Form 4: Rocket Pharmaceuticals Director Gotham Makker Receives Significant RSU Grants

Rocket Pharmaceuticals, Inc. Director Gotham Makker was granted a total of 49,434 restricted stock units (RSUs) on June 18, 2025, which are set to vest in full on June 18, 2026.

Summary

• Gotham Makker, a Director of Rocket Pharmaceuticals, Inc. (RCKT), was granted a total of 49,434 restricted stock units (RSUs) on June 18, 2025.
• The grants comprise two separate tranches: 30,000 RSUs and an additional 19,434 RSUs.
• The 19,434 RSUs were specifically issued in lieu of director retainer fees amounting to $55,000.
• All granted RSUs convert to common stock on a one-for-one basis and are scheduled to vest in full on June 18, 2026.
• Following these transactions, Dr. Makker's indirect beneficial ownership through Simran Investment Group increased to 415,346 shares.
• Additionally, Dr. Makker maintains indirect beneficial ownership of 621,500 shares through a non-revocable trust for his children, over which he disclaims voting or investment power.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is a routine compensation event that aligns the director's interests with shareholders. It is generally viewed as neutral to slightly positive, indicating continued commitment and standard governance practices, with minor dilution impact.

Positives

• The grant of 49,434 restricted stock units (RSUs) to a director aligns management's interests with shareholder value, as the value of the compensation is directly tied to the company's stock performance.
• The issuance of 19,434 RSUs in lieu of $55,000 in director retainer fees indicates a preference for equity-based compensation, which can help conserve the company's cash reserves.

Negatives

• The RSU grants will result in future dilution of existing shares upon vesting, although the impact from 49,434 shares is likely minor.

Industry Context

This Form 4 reflects standard practice in the biotechnology and pharmaceutical industries where equity compensation, particularly restricted stock units, is a common method to compensate directors and executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a common practice across the biotechnology and pharmaceutical sectors, aligning with compensation strategies seen at companies like Moderna, BioNTech, or Regeneron, which frequently use equity to incentivize and retain key personnel.
• The specific value of $55,000 in retainer fees converted to RSUs is within typical ranges for non-executive director compensation at publicly traded biotech firms of similar market capitalization to Rocket Pharmaceuticals.

Corporate Governance

Related Party Transactions

• Grant of 49,434 restricted stock units (RSUs) to Gotham Makker, a Director of Rocket Pharmaceuticals, Inc.
• Indirect beneficial ownership of 415,346 shares through Simran Investment Group, where Dr. Makker serves as Chief Executive Officer and Chief Investment Officer and exercises voting and dispositive control.
• Indirect beneficial ownership of 621,500 shares through a non-revocable trust for the benefit of Dr. Makker's children, over which he disclaims voting or investment power.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting of RSUs; improved alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of the 49,434 restricted stock units on June 18, 2026, at which point they will convert to common stock.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director compensation, equity compensation, beneficial ownership, Gotham Makker